We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




RBC Transporters Used for Targeting Nanoparticle Drug Carriers

By LabMedica International staff writers
Posted on 14 Aug 2018
Print article
Image: Red blood cells can safely transport nanoscale drug carriers to chosen organs by targeted placement of intravascular catheters (Photo courtesy of the University of Pennsylvania).
Image: Red blood cells can safely transport nanoscale drug carriers to chosen organs by targeted placement of intravascular catheters (Photo courtesy of the University of Pennsylvania).
A novel, patent pending nanoparticle drug delivery system uses red blood cells to transport drug carriers directly to selected target organs with minimal exposure to other areas of the body.

The used of nanocarriers (NCs) for drug delivery has been complicated by the dominant uptake of the particles by the liver and subsequent limited target organ deposition, even when the NCs were targeted using affinity markers.

To increase the precision of NC drug transport, investigators at the University of Pennsylvania (Philadelphia, USA) devised a universal solution: red blood cell (RBC)-hitchhiking (RH), in which NCs adsorbed onto the RBCs transferred from RBCs to the first organ downstream of the intravascular injection. This approach significantly increased the concentration of drugs ferried to selected organs.

The investigators reported the outcome of a proof-of-principle study in the July 11, 2018, online edition of the journal Nature Communications. They said in this paper that use of RH carriers increased drug uptake in the lungs by about 40-fold following intravenous injection as compared to absorption of freely circulating drug carriers. Furthermore, injection of RH drug carriers into the carotid artery delivered about 10% of the injected dose to the brain, an amount that was approximately 10 times higher than what was obtained by using antibodies to guide drug carriers to target organs. The investigators further reported that RH worked in mice, pigs, and ex vivo human lungs without causing RBC or end-organ toxicities.

“Red blood cells are a particularly attractive carrier due to their biocompatibility and known safety in transfusions,” said senior author Dr. Vladimir Muzykantov, professor of systems pharmacology and translational therapeutics at the University of Pennsylvania. “In just a few short years since we began this work, we are now on the brink of mapping out ways to test it in clinical trials. The body’s largest surface area of cell-to-cell interaction is observed between red blood cells and blood vessel linings, so it is intriguing to think that our RH technology has uncovered a phenomenon in which RBCs naturally transport cargo on their surfaces.”

Related Links:
University of Pennsylvania

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
Ultra-Low Temperature Freezer
iUF118-GX

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.